olivLaw · European equity research
Αυτοματοι Αναλυτες-Διαγνωστικα Αντιδραστηρια Και Ιδιωτικα Διαγνωστικα Εργαστηρια-Medicon Hellas Ανωνυμη Εταιρεια MEDIC.AT
Greece · Athens Stock Exchange · ISIN GRS424003002 · Vertical: Listed companies from Greece
At the close of 05 Nov 2026, Αυτοματοι Αναλυτες-Διαγνωστικα Αντιδραστηρια Και Ιδιωτικα Διαγνωστικα Εργαστηρια-Medicon Hellas Ανωνυμη Εταιρεια (MEDIC.AT) stock was 3.10 EUR (+2.65% on the day), with beta 0.39, 52-week range 2.39–3.12 EUR.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 59.9
- strong (55–70)
- Bollinger (20, 2)
- 2.90 – 3.18
- in the upper half of the band · %B 0.70 · band width 9.3%
- SMA 50 / 200
- 2.88 / 2.72
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.05 / 0.06
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +5.1% | −0.2% | +5.2 pp | — |
| 3 months | +11.9% | −5.4% | +17.3 pp | — |
| 6 months | +20.2% | +4.4% | +15.8 pp | — |
| Year to date | +22.5% | +6.5% | +16.1 pp | — |
| 1 year | +21.6% | +10.0% | +11.6 pp | +0.4% |
| 3 years | −1.6% | +48.6% | −50.2 pp | +38.4% |
| 5 years | +1.6% | +41.4% | −39.8 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 18.1 m | 18.1 m | 18.0 m |
| Revenue YoY | unavailable | +0.0% | −0.9% |
| Net income | 1.4 m | 1.3 m | 1.8 m |
| Net income YoY | unavailable | −7.6% | +32.6% |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | 8.0% | 7.4% | 9.9% |
| Free cash flow | -716.5 k | 995.4 k | 2.9 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 6.7 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 19.8 m EUR
- Total assets
- 32.7 m EUR
- Debt / equity
- unavailable
- Current ratio
- 5.18x
- ROE
- 9.2%
- ROA
- 5.5%
- FCF margin
- 16.2%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 18.1 m | 18.1 m | 18.0 m | esef· 23 Oct 2026verified |
| Cost of revenue | 5.1 m | 5.2 m | 4.8 m | esef· 23 Oct 2026verified |
| Gross profit | 13.0 m | 12.9 m | 13.1 m | esef· 23 Oct 2026verified |
| Research & development | 921.9 k | 925.2 k | 1.0 m | esef· 23 Oct 2026verified |
| Operating income | 1.8 m | 1.6 m | 2.3 m | esef· 23 Oct 2026verified |
| Depreciation & amortisation | 1.7 m | 1.7 m | 1.5 m | esef· 23 Oct 2026verified |
| EBITDA | 3.5 m ≈ | 3.4 m ≈ | 3.8 m ≈ | esef· 23 Oct 2026derived |
| Interest expense | 888.3 k | 638.0 k | 457.5 k | esef· 23 Oct 2026verified |
| Pre-tax income | 1.7 m | 1.5 m | 2.1 m | esef· 23 Oct 2026verified |
| Income tax | 273.2 k | 185.2 k | 302.8 k | esef· 23 Oct 2026verified |
| Net income | 1.4 m | 1.3 m | 1.8 m | esef· 23 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 5.5 m | 8.5 m | 6.7 m | esef· 23 Oct 2026verified |
| Inventories | 3.3 m | 2.9 m | 3.5 m | esef· 23 Oct 2026verified |
| Current assets | 21.9 m | 21.7 m | 22.7 m | esef· 23 Oct 2026verified |
| Property, plant & equipment, net | 7.2 m | 7.0 m | 7.3 m | esef· 23 Oct 2026verified |
| Total assets | 32.0 m | 31.5 m | 32.7 m | esef· 23 Oct 2026verified |
| Accounts payable | 2.8 m | 2.8 m | 3.0 m | esef· 23 Oct 2026verified |
| Current liabilities | 4.2 m | 3.9 m | 4.4 m | esef· 23 Oct 2026verified |
| Equity | 17.7 m | 18.6 m | 19.8 m | esef· 23 Oct 2026verified |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 878.3 k | 2.0 m | 4.4 m | esef· 23 Oct 2026verified |
| Capex | 1.6 m | 1.0 m | 1.5 m | esef· 23 Oct 2026verified |
| Free cash flow | -716.5 k ≈ | 995.4 k ≈ | 2.9 m ≈ | esef· 23 Oct 2026derived |
| Investing cash flow | -984.2 k | -398.2 k | -1.3 m | esef· 23 Oct 2026verified |
| Financing cash flow | -1.6 m | -1.6 m | -925.3 k | esef· 23 Oct 2026verified |
| Dividends paid | 1.3 m | 265.2 k | 574.6 k | esef· 23 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · input data missing
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 9.9% | 56 (vs peers) | 23% |
| FCF conversion · Quality | 164.5% | 100 (on a fixed band) | 23% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 4.9x | 53 (on a fixed band) | 23% |
| Current ratio · Balance sheet | 5.2x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | 19.7% | 100 (on a fixed band) | 15% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet72/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality78/100 · 2/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ΑΥΤΟΜΑΤΟΙ ΑΝΑΛΥΤΕΣ-ΔΙΑΓΝΩΣΤΙΚΑ ΑΝΤΙΔΡΑΣΤΗΡΙΑ ΚΑΙ ΙΔΙΩΤΙΚΑ ΔΙΑΓΝΩΣΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ-MEDICON HELLAS ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ (MEDIC.AT). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 18.0 m EUR in 2025; YoY growth -0.9%; net margin 9.9%; ROE 9.2%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 164.5%
- Current ratio: 5.2x
- Payout ratio (FCF): 19.7%
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Listed companies from Greece · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| EUROB.ATΤραπεζα Eurobank Ανωνυμη Eταιρεια | 16.5 bn | 12.1 | 14.0% | 39.7% | +2.7% | +32% / +165% |
| ETE.ATΕθνικη Τραπεζα Της Ελλαδος Α.ε. | 14.8 bn | 12.7 | 13.3% | 42.5% | −5.4% | +21% / +159% |
| ELPE.ATHelleniq Energy Ανωνυμη Εταιρεια Συμμετοχων | 4.9 bn | 28.2 | 6.4% | 1.5% | −9.0% | +95% / +111% |
| CENER.ATCenergy Holdings | 4.4 bn | 22.9 | 24.3% | 9.4% | +14.7% | +41% / +199% |
| BELA.ATJumbo Ανωνυμη Εμπορικη Εταιρεια | 3.7 bn | 11.5 | 21.5% | 26.0% | +7.2% | +0% / +14% |
| AKTR.ATΑκtor Ανώνυμη Εταιρεία Συμμετοχών, Τεχνικών Και Ενεργειακών Έργων | 2.0 bn | 110.6 | 6.7% | 1.3% | +11.2% | +7% / +186% |
| EYDAP.ATΕταιρια Υδρευσεως Και Αποχετευσεως Πρωτευουσης Ανωνυμη Εταιρια | 1.4 bn | — | -2.6% | -5.9% | −2.4% | +83% / +132% |
| ELHA.ATEλβαλχαλκορ Ελληνικη Βιομηχανια Χαλκου Και Αλουμινιου Ανωνυμος Εταιρεια | 1.3 bn | 12.2 | 9.8% | 2.9% | +5.1% | +4% / +80% |
| AEGN.ATΑεροπορια Αιγαιου Ανωνυμη Αεροπορικη Εταιρεια | 995.2 m | 6.7 | 27.7% | 7.9% | +4.6% | −23% / −3% |
| AVAX.ATΑβαξ Ανωνυμη Εταιρεια Εργοληπτικη-Τουριστικη-Εμπορικη-Βιομηχανικη-Οικοδομικων Υλικων & Μηχανηματων | 495.3 m | 10.4 | 25.9% | 5.0% | +47.1% | +37% / +119% |
| BYLOT.ATBally's Intralot Α.ε. | 460.2 m | 15.1 | -9.3% | -12.6% | +34.8% | +10% / +17% |
| ELLAKTOR.ATΕλλακτωρ Ανωνυμη Εταιρεια | 419.4 m | 2.7 | 26.1% | 175.2% | −74.8% | −32% / −44% |
| AEM.ATAlter Ego Media Α.ε. | 350.0 m | 17.8 | 18.3% | 14.0% | +12.6% | −3% / unavailable |
| ALMY.ATΑλουμυλ Βιομηχανια Αλουμινιου Αε | 319.4 m | 10.4 | 23.5% | 6.0% | +11.7% | +15% / +118% |
| DIMAND.ATDimand Ανωνυμη Εταιρεια Αξιοποιησης Και Εκμεταλλευσης Ακινητων Και Κατασκευων Υπηρεσιων Και Συμμετοχων | 266.7 m | 7.6 | 18.5% | 58.5% | +110.6% | +42% / +28% |
| EVR.ATΕυρώπη Holdings Α.ε. | 168.6 m | 37.2 | 2.9% | 30.7% | +435.3% | −32% / +33% |
| EYAPS.ATΕταιρεια Υδρευσης & Αποχετευσης Θεσσαλονικης Α.ε. | 166.6 m | 21.6 | 4.1% | 8.8% | +2.4% | +22% / +39% |
| BRIQ.ATBriq Properties Ανωνυμη Εταιρεια Επενδυσεων Σε Ακινητη Περιουσια | 148.6 m | 5.9 | 15.5% | 116.9% | +37.8% | +12% / +69% |
| FAIS.ATΦαις Συμμετοχων Ανωνυμη Εταιρεια | 116.3 m | 8.7 | 22.1% | 6.3% | +12.9% | −7% / unavailable |
| DAIOS.ATΔαϊος Πλαστικα Ανωνυμη Βιομηχανικη Εμπορικη Εταιρεια Α.ε. | 102.0 m | 10.3 | 14.0% | 15.6% | +9.1% | −5% / +113% |
| ASTAK.ATAlpha Real Estate Services Ae | 94.7 m | 12.6 | 10.4% | 30.3% | +22.4% | −7% / −7% |
| ASCO.ATA.s. Εμπορικη-Βιομηχανικη Εταιρια Η/υ & Παιχνιδιων Α.ε. | 59.6 m | 10.4 | 14.1% | 15.8% | +16.4% | +10% / +105% |
| AVE.ATAve Α.ε. | 50.4 m | — | -25.2% | -7.4% | +8.2% | −8% / −13% |
| ELTON.ATΕλτον Διεθνους Εμποριου Ανωνυμη Εμπορικη Βιομηχανικη Εταιρεια | 46.8 m | 13.7 | 4.9% | 1.9% | +8.6% | −12% / −19% |
| ELSTR.ATΕλαστρον Α.ε.β.ε. Χαλυβουργικα Προϊοντα | 45.7 m | 8.2 | 6.6% | 3.3% | −5.2% | +4% / −14% |
1- and 3-year price returns: for MEDIC.AT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202523 Oct 2026
- Annual report 202423 Oct 2026
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.